0
Skip to Content
Mare Healthcare
Immunoassay Brands
Roche
Abbott
Siemens
Home
Products
Articles
About
Contact
Türkçe
Mare Healthcare
Immunoassay Brands
Roche
Abbott
Siemens
Home
Products
Articles
About
Contact
Türkçe
Folder: Immunoassay Brands
Back
Roche
Abbott
Siemens
Home
Products
Articles
About
Contact
Türkçe
Products Roche SD Biosensor Covid-19 At Home Test
cps-thumbnail-sars-cov-2-rapid-antigent-self-test-nasal.jpeg Image 1 of 4
cps-thumbnail-sars-cov-2-rapid-antigent-self-test-nasal.jpeg
pst_kit_content_packshot_no-pouches_transparent_copy.jpeg Image 2 of 4
pst_kit_content_packshot_no-pouches_transparent_copy.jpeg
Roche - FDA Approval.png Image 3 of 4
Roche - FDA Approval.png
mi_sdbiosensor_230921.jpeg Image 4 of 4
mi_sdbiosensor_230921.jpeg
cps-thumbnail-sars-cov-2-rapid-antigent-self-test-nasal.jpeg
pst_kit_content_packshot_no-pouches_transparent_copy.jpeg
Roche - FDA Approval.png
mi_sdbiosensor_230921.jpeg

Roche SD Biosensor Covid-19 At Home Test

$0.00

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Roche’s COVID-19 At-Home Test.

Click here for the FDA Approval of Roche Covid-19 At-Home Test.

Click here for the User Manual of Roche (SD Biosensor) At-Home-Test.

Click here for the Clinical Evaluation Report of Roche (SDBio) Covid-19 At-Home-Test.

The COVID-19 At-Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 6 days of symptom onset.

This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 6 days of symptom onset.

This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

The COVID-19 At-Home Test does not differentiate between SARS-CoV and SARS-CoV-2.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the COVID-19 At-Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.

Add To Cart

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Roche’s COVID-19 At-Home Test.

Click here for the FDA Approval of Roche Covid-19 At-Home Test.

Click here for the User Manual of Roche (SD Biosensor) At-Home-Test.

Click here for the Clinical Evaluation Report of Roche (SDBio) Covid-19 At-Home-Test.

The COVID-19 At-Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 6 days of symptom onset.

This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 6 days of symptom onset.

This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

The COVID-19 At-Home Test does not differentiate between SARS-CoV and SARS-CoV-2.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the COVID-19 At-Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Roche’s COVID-19 At-Home Test.

Click here for the FDA Approval of Roche Covid-19 At-Home Test.

Click here for the User Manual of Roche (SD Biosensor) At-Home-Test.

Click here for the Clinical Evaluation Report of Roche (SDBio) Covid-19 At-Home-Test.

The COVID-19 At-Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 6 days of symptom onset.

This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 6 days of symptom onset.

This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

The COVID-19 At-Home Test does not differentiate between SARS-CoV and SARS-CoV-2.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the COVID-19 At-Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.

MARE HEALTHCARE

  • Click here for the Catalogue of Siemens CLINITEST Self-Test Home-use

  • Click here for the User Manual (IFU) of Siemens CLINITEST Rapid Antigen Test.

  • Click here for the FDA Approval (Emergency Use Authorization) of Siemens CLINITEST Rapid Antigen Test.

  • Click here for the Clinical Evaluation Report of Siemens CLINITEST Rapid Antigen Test.

  • Click here for Healgen Coronavirus Antigen (Swab) Test Catalogue.

  • Click here for Siemens-Healthineers and Healgen Cooperation Documents.

  • Click here for Healgen User Manual

  • Click here for Healgen Antigen Test Performance Report.

  • Click here for Healgen Antigen Test Stability Report.

  • Click here for Healgen Coronavirus test Booklet.

  • Click here for the Germany Health Ministry and Paul Ehrlich Institute’s Comparative Report on 122 Covid Antigen Test Brands

 

MARE HEALTHCARE

www.marehealthcare.com

info@marehealthcare.com


+90(533) 965-7532